{"disease":{"id":"maroteaux-lamy-syndrome","name":"Maroteaux-Lamy syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"galsulfase","indication_name":"Maroteaux-Lamy syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aryplase","generic_name":"GALSULFASE","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":59,"revenue":"400","mechanism":"Aryplase breaks down accumulated glycosaminoglycans in lysosomes to treat Maroteaux-Lamy syndrome."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02171104","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":149,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT02156674","title":"Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome","phase":"NA","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}